MK0429 Study in Prostate Cancer Patients With Metastatic Bone Disease (0429-011)
This two part study will evaluate the safety and tolerability of MK0429 in addition to assessing it's pharmacokinetic profile and pharmacodynamic response.
Prostatic Neoplasms
DRUG: Comparator: MK0429|DRUG: Comparator: MK0429|DRUG: Comparator: MK0429|DRUG: Comparator: MK0429
Safety and tolerability of 4 weeks of MK0429 therapy., up to 14 days following last dose of medication
Part 1: Pharmacokinetic profile of MK0429 and pharmacodynamic responses to treatment of MK0429, 4 weeks|Part 2: Pharmacokinetic profile of MK0429 [Time frame 4 weeks] and pharmacodynamic responses to treatment of MK0429 [Time frame 8 weeks], 4 weeks and 8 weeks
This two part study will evaluate the safety and tolerability of MK0429 in addition to assessing it's pharmacokinetic profile and pharmacodynamic response.